Business
Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Aim is to Predict Oncology Outcomes using Multimodal Artificial Intelligence VANCOUVER, BC / ACCESS Newswire / May 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco") is pleased to announce that its ...
About this update from Onco-innovations Ltd.
[{"type":"text","content":"Aim is to Predict Oncology Outcomes using Multimodal Artificial Intelligence","length":76,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / May 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. (together with Onco, the "Company"), has entered into a research collaboration with AstraZeneca, a global biopharmaceutical company. This work forms part of the Company's PROmAI program, short for Predicting Oncology Outcomes using Multimodal Artificial Intelligence, focused on advancing predictive modelling capabilities in oncology through multimodal artificial intelligence.","length":616,"tagName":"p"},{"type":"text","content":"The work centers on the development and evaluation of AI-based approaches designed to improve the prediction of clinical outcomes in oncology. The joint effort will assess multimodal approaches using deidentified research datasets provided under the collaboration, including molecular, clinical and imaging sources, where permitted, to better understand patient heterogeneity and treatment response patterns. The initiative reflects a shared objective to strengthen decision support tools that can inform translational research, clinical development strategy and the design of future oncology studies.","length":601,"tagName":"p"},{"type":"text","content":"This project represents a significant milestone in Onco's strategy to apply advanced AI to complex problems in oncology drug development. The collaboration creates a structured environment for generating insights that can support more reliable and clinically meaningful predictive modelling. The work aims to contribute to frameworks that enhance interpretability, align with evolving expectations from regulators and payers and ultimately improve the utility of AI-driven methods in oncology research.","length":506,"tagName":"p"},{"type":"text","content":"For the Company, the collaboration with AstraZeneca provides the opportunity to work closely with a global leader in oncology innovation. Through this collaboration, Onco aims to demonstrate how multimodal and causal AI techniques can support the development of more precise predictive tools with the potential to impact the future of oncology rese...